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Abstract: The pharmaceutical industry stands at a peculiar place in the United
States. It is one of the largest industries in the United States, “enjoy[ing] profit
margins nearly four times that of the average Fortune 500 company.” It is also
a global leader, responsible for an enormous amount of research and
development. Despite its size and power, the U.S. pharmaceutical industry is
largely reviled, Perhaps what differentiates the U.S. pharmaceutical industry
from the pharmaceutical industries of other nations is its “free market” price
setting. Other nations, particularly those in the European Union, use
government price controls to keep pharmaceutical prices low. One of the most
popular systems of price control is reference pricing. Reference pricing is a
method of controlling spending on drug reimbursement by using the price of
similar or existing drugs to set “a reimbursement tariff (called reference price)
for groups of drugs which are considered to be ‘interchangeable.’” This
Comment explores the validity of reference pricing as a method of reducing
government healthcare spending, particularly in the United States, through
comparison to foreign price controls.
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I. INTRODUCTION
The pharmaceutical industry stands at a peculiar place in the United
States. It is one of the largest industries in the United States, “enjoy[ing]
profit margins nearly four times that of the average Fortune 500 company.”1
It is also a global leader, responsible for an enormous amount of research
and development. Despite its size and power, the U.S. pharmaceutical
industry is largely reviled. “Big Pharma” casts a shadow over national
dialogue—both the formal public dialogue through the media and the more
informal dialogue which takes place across the internet.2 Perhaps what
differentiates the U.S. pharmaceutical industry from the pharmaceutical
industries of other nations is its “free market” price setting. Other nations,
particularly those in the European Union, use government price controls to
keep pharmaceutical prices low. One of the most popular systems of price
control is reference pricing. Reference pricing is a method of controlling
spending on drug reimbursement by using the price of similar or existing
drugs to set “a reimbursement tariff (called reference price) for groups of
drugs which are considered to be ‘interchangeable.’”3
This Comment explores the validity of reference pricing as a method
of reducing government healthcare spending, particularly in the United
States, through comparison to foreign price controls. Part II discusses the
features of reference pricing and describes the various forms that reference
pricing takes within the European Union. Part III focuses on Germany and
its unique place in the European Union as a reference country, while Part IV
analyzes reference pricing as it is used in France. Finally, Part V discusses
the current state of healthcare and pharmaceutical industries in the United
States and argues that a system of reference pricing will be effective in the
United States, particularly under the Affordable Care Act.

1
Jerry Stanton, Comment, Lesson for the United States From Foreign Price Controls on
Pharmaceuticals, 16 CONN. J. INT’L L. 149, 154 (2000).
2
A Google search for the much-touted phrase “big pharma” reveals a variety of sites of questionable
veracity, including everything from “mommy bloggers,” to a natural lifestyle website, to mass market
books like the following: JACKY LAW, BIG PHARMA: HOW THE WORLD’S BIGGEST DRUG COMPANIES
CONTROL ILLNESSES (2006).
3
CHRISTINE HUTTIN, Experiences with Reference Pricing, in DRUGS AND MONEY — PRICES,
AFFORDABILITY, AND COST CONTAINMENT 85 (C.P. de Joncheere et al. eds., 7th ed. 2003), available at
http://apps.who.int/medicinedocs/pdf/s4912e/s4912e.pdfhttp://apps.who.int/medicinedocs/
en/d/Js4912e/3.3.html#Js4912e.3.3.
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II. REFERENCE PRICING DEFINED
Many countries use reference pricing as a method for pricing
pharmaceuticals for government reimbursement.4 Reference pricing is
usually enacted through a healthcare reform law, and then put into action
through specially created government committees or already existing public
health committees.5 Under reference pricing, interchangeable medicines6
are divided into groups.7 The prices of these drugs are then compared to the
prices for the same drugs in select international markets and set
accordingly.8 Which countries are used for comparison is either specified in
the originating law or determined by a government agency.9
After reference prices are set, if a pharmaceutical company continues
to price their medication beyond the reference point, the consumer must pay
the additional cost beyond the reference price.10 Typically, neither a
consumer’s insurance nor the government payor system pays the difference,
though some private insurance plans or “luxury” additional insurance plans
do cover higher cost drugs.11 These systems are utilized in virtually every
developed nation outside of the United States.12
Though some countries utilize reference pricing as an informal
benchmark, many have codified reference pricing in their regulatory

4
Lana Kraus, Note, Medication Misadventures: The Interaction of International Reference Pricing
and Parallel Trade in the Pharmaceutical Industry, 37 VAND. J. TRANSNAT’L L. 527, 529 (2004). The
terms “reference pricing” and “international reference pricing” are used interchangeably throughout this
Note—merely reflecting the U.S.-based perspective of the analysis—because the United States does not
currently use a system of reference pricing.
5
Reference Prices and How They Are Set, GEMEINSAMER BUNDESAUSSCHUSS (Feb. 9, 2014),
http://www.english.g-ba.de/special-topics/pharmaceuticals/reference/; Kraus, supra note 4, at 536.
6
Interchangeable medicines are typically biosimilars or bioequivalents. For an explanation of how
these are defined, see subpart II(A).
7
Pieter Dylst et al., Reference Pricing Systems in Europe: Characteristics and Consequences, 1
GABI J. 127, 128 (2012).
8
The exact calculations in arriving at this number depend on what a given government chooses to
base their reference pricing on. Some calculation systems, which will be discussed hereinafter, include
but are not limited to the following: average price of medicines, average price of generic medicines,
lowest-priced generic, and more complex systems which balance weighted averages or take into account
a larger number of low-priced generics. See Dylst, supra note 7.
9
For a more detailed discussion of how these countries are chosen, see subpart II(A).
10
See Lisa Brandt, Price Tagging the Priceless: International Reference Pricing for Medicines in
Theory and Practice, EUROPEAN CENTRE FOR INTERNATIONAL POLITICAL ECONOMY, at 2 (2013),
available at http://www.ecipe.org/app/uploads/2014/12/ECIPE_Policy_Brief_IRP_30_May_FINAL_
pdf.pdf; PHARMACEUTICAL BENEFITS BOARD, THE SWEDISH PHARMACEUTICAL REIMBURSEMENT
SYSTEM - A BRIEF OVERVIEW 8 (2007) [hereinafter TLV], available at http://www.tlv.se/Upload/
English/ENG-swe-pharma-reimbursement-system.pdf.
11
See sources cited supra note 10.
12
Brandt, supra note 10; Stanton, supra note 1.
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systems.13 However, these systems are not regulated by any international
body. Instead, international reference pricing is governed and defined by
each country that elects to utilize such a system. In general, countries which
institute reference-pricing systems have some semblance of “socialized
medicine.”14 Additionally, almost all reference-pricing countries base their
pricing models largely on countries with low pharmaceutical prices.15
However, because there is no governing body managing the prices
governments set for pharmaceuticals, each government utilizing reference
pricing has a great deal of discretion in setting prices and negotiating with
pharmaceutical companies. This can result in a large disparity in
pharmaceutical prices between different countries, at times seemingly at
odds with the per capita income of these countries, leading to poorer
countries paying high prices for pharmaceuticals.16
A. How Reference Groups are Defined
Reference groups are established based on three basic identifiers either
alone or in combination. These identifiers are the following: active
substance or ingredient, pharmacological class, and therapeutic class.
Active ingredient is defined by the World Health Organization (WHO)
as “‘[a]ny substance or combination of substances used in a finished
pharmaceutical product (FPP), intended to furnish pharmacological activity
or to otherwise have direct effect in the diagnosis, cure, mitigation,
treatment or prevention of disease, or to have direct effect in restoring,
correcting or modifying physiological functions in human beings.’”17
13

See generally U.S. DEP’T OF COMMERCE, INT’L TRADE ADMIN., PHARMACEUTICAL PRICE
CONTROLS IN OECD COUNTRIES IMPLICATIONS FOR U.S. CONSUMERS, PRICING, RESEARCH AND
DEVELOPMENT, AND INNOVATION [hereinafter ITA], available at http://www.ita.doc.gov/td/
chemicals/drugpricingstudy.pdf.
14
Socialized medicine, however, is generally a term only used by the U.S. media.
15
Although they are not included in this comparison, this particular feature of International
Reference Pricing may have an extremely detrimental effect on developing nations. Drug developers
have historically offered lower-price drugs to developing nations, particularly in instances of outbreak or
pervasive disease, as well as diseases which develop due to lack of clean food and water which are
common in developing nations. When developed nations craft reference prices, they often bundle these
lower-priced drugs into their averages. As a result, drug developers’ profits suffer because the
reimbursement price is lowered in developed nations, which make up the majority of their profit
margins. Perhaps as a result of this, drug companies have displayed reluctance to provide low-cost drugs
to developing nations. See Patricia Danzon & Adrian Towse, Differential Pricing for Pharmaceuticals:
Reconciling Access, R&D and Patents, 3 INT’L J. HEALTH CARE FIN. & ECON. 183, 185 (2003).
16
These differences are often held as the reason behind the thriving black or grey markets in
international pharmaceuticals, notably, between the United States and Canada. See Paula Tironi, Article,
Pharmaceutical Pricing: A Review of Proposals to Improve Access and Affordability of Prescription
Drugs, 19 ANNALS HEALTH L. 311, 351 (2010).
17
World Health Organization, Definition of Active Pharmaceutical Ingredient (World Health Org.,
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Generic drugs are bioequivalents of name brand drugs, meaning that the
active ingredient is functionally or literally the same and is delivered in a
similar dosage. Beyond these active ingredients, generics can differ in their
fillers, colorants, binding agents, and other elements.18
Reference groupings based on active ingredient does not take such
nonactive differences between generic and name brand drugs into account
while creating medication groups. Such a system may encourage the
manufacture of biosimilars, or medications which have a similar therapeutic
effect but are based on a different active ingredient. These medications
would be classified in different reference groups and would be priced
differently.19 A biosimilar without a generic substitute, for example, would
fare well in a system which allowed it to be priced independently of a
medicine with a similar effect but many generic versions.20 Countries which
define reference groups based on active ingredient include Belgium,
Finland, France, and Hungary.21 This method is the most popular method of
defining reference groups.22
Another method of crafting reference groups is by pharmacological
class. “[A] pharmacologic class is a group of drugs that share scientifically
documented properties.”23 These documented properties might include the
mechanism of action (the effect of the drug “at the receptor, membrane, or
tissue level”), physiologic effect “at the organ, system, or whole body
level,” or the chemical structure of the drug.24 In the United States, the Food
Working Document QAS/11.426/Rev.1, 2011), available at http://www.who.int/medicines/areas/
quality_safety/quality_ assurance/DefinitionAPI-QAS11-426Rev1-08082011.pdf.
18
See Colleen Kelly, The Balance Between Innovation and Competition: The Hatch-Waxman Act,
the 2003 Amendments, and Beyond, 66 FOOD DRUG L.J. 417 (2011); Adam R. Young, Note, Generic
Pharmaceutical Regulation in the United States with Comparison to Europe: Innovation and
Competition, 8 WASH. U. GLOBAL STUD. L. REV. 165 (2009).
19
See Kraus, supra note 4.
20
This is similar to a common occurrence in the United States where pharmaceutical companies
fight to maintain a market share upon the expiration of their patent. Pharmaceutical companies will often
develop a similar product that is functionally altered enough to warrant a new patent—for example, an
extended-release version of a medicine which has the same overall effect. These incremental changes
are used to “evergreen” the company’s patent protection. When patients are prescribed this new version
of the medication, a generic version does not exist to be substituted. See generally Steven Johnson,
Innovation: It Isn’t a Matter of Left or Right, N.Y. TIMES (Oct. 30, 2010),
http://www.nytimes.com/2010/10/31/business/31every.html?pagewanted=all; Jonathan Cohn, Creative
Destruction, NEW REPUBLIC (Nov. 12, 2007), http://www.newrepublic.com/article/politics/creativedestruction.
21
Dylst et al., supra note 7.
22
Id.
23
U.S. DEP’T OF HEALTH AND HUMAN SERV. ET AL., GUIDANCE FOR INDUSTRY AND REVIEW STAFF
LABELING FOR HUMAN PRESCRIPTION DRUG AND BIOLOGICAL PRODUCTS — DETERMINING
ESTABLISHED PHARMACOLOGIC CLASS FOR USE IN THE HIGHLIGHTS OF PRESCRIBING INFORMATION, at
3 (Oct. 2009).
24
Id.
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and Drug Administration (FDA) has established pharmacological classes
based on these factors. Upon development, drugs can be classified into an
existing pharmacological class if they fit within the criteria. The FDA has
also established a practice for establishing new pharmacologic classes
(though pharmacological classes are not then used for reference pricing in
the United States).25 Developed foreign nations have enacted similar
government processes.26 Pharmacologic classification, as well as
therapeutic class—the classification of a drug based on the condition or
disease it treats, rather than the more specific biological effect encompassed
under pharmacologic class27—can lead to a wider variety of medications
being contained within a certain reference price group. Grouping by
pharmacologic or therapeutic class can be a more effective price control
because it allows the price regulations to contain a larger span of
medications within a single price group. However, grouping by
pharmacologic or therapeutic class may also lead to undesirable patient
outcomes as doctors are incentivized to choose medicines based on
financial reasons rather than medical reasons.28
B. How Reference Prices are Crafted
Once drug classes are determined, individual drugs’ reference prices
are generally calculated “as a function of market prices of medicines.”29
However, which medicines that are taken into account in considering the
market price varies widely among different countries within and outside of
the European Union. Croatia and Hungary, for example, set reference prices
based on the average price of all medicines within a group. Other methods
include setting prices by the lowest price in a group, pricing based on the
generic drug market, and pricing by lowest price overall.
By far, the most popular method is to set the reference price for a
designated group of drugs—often separated by class—based on other
countries’ lowest priced medicines within that designated group’s reference
points. Bulgaria, the Czech Republic, Finland, Italy, Poland, Spain, and
Turkey use this method alone or in addition to other methods.30 While
25

Id. at 6.
See generally Drummond et al., Reimbursement of Pharmaceuticals: Reference Pricing Versus
Health Technology Assessment, 12 EUR. J. HEALTH ECON. 263 (2011); Kraus, supra note 4.
27
Kraus, supra note 4. The difference between pharmacologic and therapeutic classification is subtle
but important. Pharmacological class is grouped solely by the drug’s effects on the body, while
therapeutic class focuses on the particular disease or condition the drug is intended to treat. These
groups often overlap, but can also diverge strongly.
28
Danzon, supra note 15; Stephen A. Talmadge, Influencing Physicians’ Prescribing Behavior:
Ethical Issues Related to Pharmaceutical Gifts, 11 MICH. ST. U. J. MED. & L. 303, 311 (2008).
29
Talmadge, supra note 28.
30
Id.
26
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lower priced medicines often include generic medicines simply because
generic medications are priced on a different scale by companies (which
usually do not need to account for research and development in pricing
generics), this method does not focus specifically on generic medicines in
assigning prices and often includes competitively priced name brand
drugs.31
Pricing by lowest price overall, however, may undermine the
development of generic drug markets in countries where lowest price is
used without special attention to generics. The generic market depends on
competitive prices to sustain itself because generic manufacturers are not,
for the most part, companies that also develop new drugs for the market. A
system based on lowest price urges developers of name brand drugs to
compete on price with generics because they can no longer be guaranteed a
premium for their product.32 This is undesirable to originators as well
because they spend millions on research and development and rely on
higher prices to recoup these costs.
Some nations, which place more importance on a national market for
generic medicines, have based their reference prices directly on generic
medicines alone. In France, reference prices are set by looking to the
average price of generic medicines within a designated group or class in
chosen reference countries, while Denmark and Latvia use a similar system
based on the lowest priced generic medicine.33 Countries which base
reference prices on generics generally intend reference pricing to serve in
part as a mechanism to grow the market of generic pharmaceuticals.
Continuing decreases in price are obviously a positive result for
government payors and consumers in terms of cost, but can result in a
pricing “race to the bottom” that places insurmountable strain on
pharmaceutical manufacturers.34
C. Effect of Reference Pricing on Foreign Governments and
Pharmaceutical Companies
Foreign governments, particularly in the European Union, are
increasingly looking to regulate healthcare across the board. As populations
age, medical treatments become more sophisticated and healthcare costs
rise. Reference pricing is an effective way for government payors to limit
what they spend on pharmaceuticals. In the United States, a country which
31
For a discussion of generic pricing models, see Generic Drugs Don’t Necessarily Mean Low
Prices, PBS NEWS HOUR, (Nov. 2, 2013, 12:00 AM), http://www.pbs.org/newshour/bb/health/julydec13/costlygenrics_11-02.html.
32
Young, supra note 18, at 183.
33
Id. at 182 n.98.
34
Id.
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allows pharmaceutical companies near unbridled discretion in setting
prices, the government spends approximately 8%–10% of its total health
care costs on pharmaceuticals.35 In most other countries, reference pricing
has been an effective method of cost saving and could be equally effective
in the United States.
Poland, for example, had a remarkably underfunded and inefficient
healthcare system in the past, spending 0.63% of its Gross Domestic
Product (GDP) on pharmaceutical reimbursements and 7% on health care
overall. At the same time, Poland’s medical industry delivered a poor level
of care (for example, Poland demonstrated the lowest level of access to
cancer treatment in the EU).36 However, in 2012, Poland implemented
health care reforms which, among other improvements, refined the system
of reference pricing and applied more stringent caps on pharmaceutical
reimbursements. In the same year, Poland saw, for the first time, a decrease
in prescription reimbursement costs.37 This decrease in costs did not further
reduce quality of care, and Poland has since realized steady improvements
in quality of care.38
Canada has also experienced great success through reference pricing.
In the early 1990s, Canada began reforming their drug patent and pricing
system in response to the North American Free Trade Agreement
(NAFTA).39 Canada established the Patented Medicines Price Review
Board (PMPRB), which compares drug prices in Canada to foreign prices
for the same drug or a similar compound. For innovative medicines, prices
are compared to nine other countries. For similar compounds (generics),
prices are set closely to preexisting drugs internally. Since the creation of
the PMPRB, drug prices have been consistently below the Canadian
consumer price index.40
Other countries, however, have used reference pricing as a method of
controlling pharmaceutical spending in the past and subsequently
abandoned it. Between 1993 and 2003, Sweden used a form of international
35

Stanton, supra note 1.
Joanna Lis, President of Polish Int’l Society for Pharmacoeconomics and Outcomes Research
(ISPOR) Chapter, Address at ISPOR 18th Annual Meeting: Pricing of Pharmaceuticals in Emerging
Countries of the Central & Eastern European Region: The Case of POLAND 2 (May 21, 2013),
available at http://www.ispor.org/meetings/neworleans0513/releasedpresentations/FORUM-2-Central_
Eastern_Europe_Lis.pdf.
37
Id.
38
Id.
39
This reform was largely because Canada’s patent protections included compulsory licensing
provisions that did not conform to NAFTA. NAFTA eliminated all compulsory licensing with a few
exceptions. In anticipation of this change, Canada passed a law commonly known as C-91, which
updated their patent laws to conform with NAFTA. Though controversial, C-91 was renewed in 1997.
Stanton, supra note 1, at 160.
40
Stanton, supra note 1, at 161.
36
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reference pricing based on chemical equivalency and active ingredients.41 In
2003, however, Sweden replaced this system with a drug substitution
scheme. The Swedish Pharmaceutical Benefits Board cited three reasons for
the change. First, the cost of reimbursed drugs was increasing. Second,
Sweden’s reimbursement system was overly generous. Finally, the Board
was concerned about value received for spending.42 Under the drug
substation scheme system, pharmacies select the appropriate lowest priced
drug.43 Sweden now uses a government board, the Dental and
Pharmaceutical Benefits Agency (TLV), to decide on reimbursement levels
for new drugs. The TLV does not use reference pricing to establish
reimbursement levels. Rather, it uses a product-oriented system44 that
allows for more flexibility than strict reference pricing in reimbursement
and a generic substitution scheme similar to that used by insurance policies
in the United States.45 Generic substitution is mandatory in Sweden. If a
patient chooses to reject a generic drug, they must pay the difference for the
name brand.46
Reference pricing has an impact beyond the particular country
imposing regulations because of the relatively small market share of foreign
pharmaceutical companies in comparison to powerhouse pharmaceutical
companies within the United States. In 2012, pharmaceutical research and
development expenditures in the United States topped $36,810 million,
while all European countries combined spent an estimated €30,000 million
(roughly $40.5 million). Similarly, European countries developed fifty-five
new chemical or biological entities from 2008 to 2012, while the United
States developed sixty-five (Japan, a distant third, produced twenty-six,
while all other nations produced sixteen).47 Still, any analyses of price
impacts on pharmaceutical companies must take into account both foreign
and U.S. developers who distribute to foreign markets.
41

Drummond, supra note 26.
TLV, supra note 10, at 2.
43
Many states in the United States have adopted a similar system through generic substitution laws.
Jesse C. Vivian, Generic-Substitution Laws, 33 U.S. PHARM. (GENERIC DRUG REVIEW) 30 (2008).
44
TLV clarifies that a product-oriented system means “that medicines are either granted
reimbursement status for the whole of its approved area of use or not at all.” TLV, supra note 10, at 4.
45
Danzon, supra note 15, at 13.
46
TLV, supra note 10, at 4.
47
This number represents a gradual change from decades past. From 1993 to 1997, Europe led
development with ninety new chemical and biological entities compared to the United States’ sixty-six
and Japan’s sixty. Europe’s numbers gradually decreased and were eclipsed by the United States from
1998 to 2002. These numbers have improved since 2007, but still demonstrate a disparity in production,
especially in light of the fact that Europe is considered as a whole, while the United States represents a
single country. ECORYS RESEARCH AND CONSULTING, COMPETITIVENESS OF THE EU MARKET AND
INDUSTRY FOR PHARMACEUTICALS — VOLUME I: WELFARE IMPLICATIONS OF REGULATION (2009),
available at http://ec.europa.eu/enterprise/sectors/healthcare/files/docs/vol_1_welfare_implications_
of_regulation_en.pdf.
42

422

5SALTER.DOCX (DO NOT DELETE)

9/29/15 1:56 PM

Reference Pricing and the United States
35:413 (2015)

Regardless of the production disparity between the United States and
Europe, European pharmaceutical companies expressed concern as a
growing number of governments began regulating pharmaceutical pricing.
Industry members feared “the growing practice by government health
agencies to agree or set medicine prices by reference to other countries’
prices,” and predicted that the lowest-common-denominator principle
would result in an overall lowering of profit margins throughout the
industry.48 These fears were perhaps justified, if not at the disastrous level
indicated. In 2003, a study of Organization for Economic Cooperation and
Development (OECD) countries based on U.S. Department of Commerce
calculations compared estimated revenues for a group of patented drugs
based on unregulated markets with actual profits from this set of drugs in
various countries with extensive price regulations.49 Among the countries
studied were France, Germany, Switzerland, and the UK.50 Each of these
counties uses price controls of some sort, with Germany and France giving
the most weight to reference prices within their pricing methodologies. In
France, estimated revenues for reference-priced patented drugs were $5.3
billion,51 while actual revenues were $3.8 billion. Similarly, estimated
revenues in Germany were $4.7 billion, while actual revenues were $3.5
billion.52
These revenue differences and the anticipation of falling revenues can
have a direct effect on the behavior of pharmaceutical companies in four
ways. First, it may influence where companies initially choose to release
and market drugs.53 It is in a pharmaceutical company’s best interest to
originate a drug in a country where they are free to set the price according
to their own pricing models—allowing them to potentially recoup research
and development costs that are not taken into account when setting
reference prices. Understandably, these countries might be less receptive to
high prices if a drug has already launched at a lower price in other
countries.54
Second, companies will attempt to ensure higher prices in other
countries through gaming reference lists. Originating drugs in countries
48
Pharma “is Losing Control of Pricing, and Must Present a United Case Now:” KPMG,
PHARMALETTER
(June
17,
2002)
[hereinafter
Pharmaletter],
available
at
http://www.thepharmaletter.com/article/pharma-is-losing-control-of-pricing-and-must-present-a-unitedcase-now-kpmg.
49
See ITA, supra note 13, at fig. 5.
50
See id.
51
Using U.S. Dollars as the standard currency unit.
52
ITA, supra note 13, at fig. 5.
53
Drummond et al., supra note 26.
54
Peter J. Rankin et al., Global Pricing Strategies for Pharmaceutical Product Launches, in THE
PHARMACEUTICAL PRICING COMPENDIUM 5 (2003), available at http://www.crai.com/sites/default/
files/publications/Global-Pricing-Strategies-for-Pharmaceutical-Product-Launches.pdf.
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without pricing regulations creates a higher reference point for pricing when
the drug is launched in countries that consider the “first-launch” country as
a reference point in their analysis.55 While countries generally seek lower
priced reference points rather than highly priced, first-launch prices,
pharmaceutical companies working in referenced-priced systems attempt to
force pricing lists as high as possible.56
Third, beyond the ability to set their own prices, pharmaceutical
companies give preference to countries that allow them to negotiate a
pricing and reimbursement scheme before marketing authorization is
granted, which allows them to gain a clearer picture of the gains of the
marketplace before taking substantive steps towards launching the drug.57
Finally, reference-pricing systems may also have an effect on research
and development in European markets because these costs are less likely to
be recouped. According to a 2009 study by independent consultants
analyzing the European pharmaceutical market, price regulations “will
lower a firm’s expected returns to R&D and reduce the demand for R&D
investments.”58 However, this is not based on direct numbers, but on a
projection study based on research and development in the United States.59
While the potential effect of reference pricing on research and development
in the U.S. pharmaceutical industry will be discussed in Part IV, it is
difficult to assign reference pricing as causation rather than correlation in
relation to European research and development decreases.
III. FRANCE & GERMANY
Germany, a major pharmaceutical market in the European Union, does
not use a strict reference pricing system. However, Germany was one of the
first countries to utilize reference pricing and was often looked to by other
countries in setting their pharmaceutical prices.60 Because of this, price
changes in Germany have the potential to create wide ripple effects beyond
Germany itself.
Germany requires health coverage for all citizens. In turn, 90% of

55

Id.
Id. at 52; Drummond et al., supra note 26.
57
KAI RUGGERI & ELLEN NOLTE, RAND CORP., PHARMACEUTICAL PRICING: THE USE OF
EXTERNAL REFERENCE PRICING (2013), available at http://www.rand.org/content/dam/rand/
pubs/research_reports/RR200/RR240/RAND_RR240.pdf.; Patricia M. Danzon & Jonathan D. Ketcham,
Reference Pricing of Pharmaceuticals for Medicare: Evidence from Germany, The Netherlands and
New Zealand (Nat’l Bureau of Econ. Research, Working Paper No. 10007, 2004); Dylst et al., supra
note 7.
58
RUGGERI & NOLTE, supra note 57.
59
Id.
60
Danzon, supra note 15.
56
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German citizens are covered by federal statutory health insurance (SHI).61
The German healthcare system is regulated “within the Social Code Book V
(Sozialgesetzbuch), which sets out the overall framework for the statutory
health insurance system . . . , including coverage and reimbursement of
medicines under the statutory system.”62 Article 78 of the Pharmaceutical
Act, passed in 1976, regulates prescription medication safety and states that
the Ministry of Economics and Technology must supervise the
pharmaceutical pricing.63
Manufacturers primarily drive German pharmaceutical prices.64 Highly
innovative drugs in particular are not subject to reference prices, and
manufacturers can set prices at will. However, a complex system of
regulations and internal referencing influence reimbursement rates for SHI.
Manufacturers are required to provide rebates to SHI funds, which differ
depending on whether the drug in question is a patented innovative drug or
an off-patent, generic drug.65 Additionally, hospitals may negotiate rebates
for inpatient drugs, and manufacturers may negotiate with retailers for
discounts or rebates.66 In short, the German pharmaceutical market is more
regulated than it appears on its face.
In 2007, Germany instituted healthcare reform.67 In November 2010,
the Act on the Reform of the Market for Medicinal Products (ANM) was
passed which stipulated that “from 2011 all newly licensed medicines are
subject to a (‘early’) benefit assessment; this assessment forms the basis for
determining the price of the new product.”68 Manufacturers must submit a
dossier to the Federal Joint Committee supporting the benefit of the drug,
and indicating that the drug is recently licensed for use or for a new
therapeutic indication. The Committee then releases a report describing,
among other things, “requirements for appropriate use and costs.”69 The
report is used as the basis for pricing the product.
France, another country which utilizes price limits, uses various factors
to set price limits, including reference prices. France also considers
therapeutic merit and the economic contribution of the drug.70 Beyond these
overarching factors, France looks at particular drugs to consider what
proportion of the overall national drug expenditure they make up. If a
61
62
63
64
65
66
67
68
69
70

Id. at 41.
Id.
Id.; Dylst et al., supra note 7.
RUGGERI & NOLTE, supra note 57, at 41.
Id. at 42.
Id.
Id.; Dylst et al., supra note 7.
RUGGERI & NOLTE, supra note 57, at 43.
Id.
Id. at 39.
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particular drug is a large portion of national expenditures, a cap is applied
on what the government will pay for that particular drug.71 This system of
capping frequently prescribed drugs may be very useful in the United
States. In particular, this would be useful in relation to drugs that treat
diseases that are growing more common in the United States, such as
diabetes and other obesity related illnesses.
IV. REFERENCE PRICING WOULD BE AN EFFECTIVE SYSTEM
IN THE U.S.
International Reference pricing is increasingly common and has
proven effective in foreign markets, especially in Europe.72 However, it is
not currently used in the U.S. Now, as U.S. healthcare reform is a popular
topic, the opportunity exists to bundle pharmaceutical pricing reform into
other healthcare reforms just as other countries have introduced reference
pricing through healthcare reform.73 Part IV considers the application of
reference pricing to the U.S. pharmaceutical market. Subpart A describes
the current system of pricing in the U.S. and the restrictions placed on the
pharmaceutical industry, particularly through patent law. It also describes
regulated pricing already in effect—Medicare, Medicaid, and specialized
pricing for veteran services. Subpart B considers the impact of a pricing
change on the pharmaceutical industry, while subpart C analyzes the
potential effects such a change could have on patients and providers.
Subpart D looks to the recently enacted Affordable Care Act and how a
reference-pricing system would be affected by the Act.
A. The Current State of Pharmaceutical Pricing in the United States
The United States is the only developed nation that does not use some
sort of government regulation to control pharmaceutical pricing.74 The U.S.
government, like other developed nations, regulates the health and safety of
its citizens.75 Part of this regulation includes the distribution and
manufacture of pharmaceuticals,76 much of which is executed under the
Federal Food, Drug, and Cosmetic Act (FFDCA).77 Under the FFDCA, the
government interacts directly with pharmaceutical manufacturers by
collecting fees and regulating the process of releasing drugs to the market,
71
72
73
74
75
76
77
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as well as evaluating the safety of those drugs for consumers.78 Through the
FFDCA, manufacturers must complete and file “new drug applications.”
These applications must include extensive reports detailing “the safety and
effectiveness of the drug; a full statement of the composition of the drug; a
full description of the methods, facilities, and controls used at all levels of
production; samples of the drug; and specimens of the labeling that may be
used for the drug.”79
Despite these regulations, the United States differs from other
developed nations in that manufacturers usually set pharmaceutical pricing.
Pharmaceutical innovators—manufacturers that research and develop new
drugs—obtain FDA approval and patent protection as the drug moves
through several testing phases.80 At this point, patent protection allows
originators to charge monopoly prices for the duration of the patent.81
Companies balance a variety of factors to set drug prices. The most obvious
of these is research and development expenditure because companies seek
to recoup their investment. However, since drug prices are largely inelastic
(increasing the price does not decrease the demand), companies also take
into account how much insurers and patients will value the drug, the current
marketplace, and a variety of other factors.82
Nevertheless, some price-control mechanisms do exist. Such
mechanisms include government actions which affect the entire
pharmaceutical industry, like the Hatch–Waxman Act, a bill which
encourages generic production by expediting the process of generic drug
approval.83 However, the United States has also engaged in more limited
price setting through programs like Medicare, Medicaid, and the
Department of Veterans Affairs insurance plans. These smaller price
controls more closely resemble the price controls used in other developed
nations, and use reference pricing in various ways to create price limits.
1. The Hatch–Waxman Act
Traditionally, the U.S. patent system has protected drug originators
78

Id.
Vaishali V. Shah, Note, Prescription Drugs in America: The Pain of Pricing has an Unpromising
Cure, 2006 U. ILL. L. REV 859, 861 (2006).
80
Seth D. Knocke, Incentivizing Innovation: Pharmaceutical Pricing in the United States and the
United Kingdom, 20 ANNALS HEALTH L. ADVANCE DIRECTIVE 177, 179 (2011).
81
Tironi, supra note 16, at 323.
82
See Barry Werth, A Tale of Two Drugs, MIT TECH. REV. (Oct. 22, 2013),
http://www.technologyreview.com/featuredstory/520441/a-tale-of-two-drugs/ (describing French drug
maker Sanofi’s fatal misstep in overpricing drug Zaltrap when a near equivalent drug already existed at
a much lower price).
83
See, e.g., D. Christopher Ohly & Sailesh K. Patel, The Hatch-Waxman Act: Prescriptions for
Innovative and Inexpensive Medicines, 19 U. BALT. INTELL. PROP. L.J. 107 (2011).
79
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from losing a large market share to bioequivalent competitors who release
equivalent drugs and capture market share by offering lower prices.84 The
U.S. patent system originates from Article 1 of the Constitution, which
states that Congress shall have the power “to promote the progress of
science and the useful arts, by securing for limited times to authors and
inventors the exclusive right to their respective writings and discoveries.”85
Patent protections encourage development by providing companies the
opportunity to potentially recoup the costs of research and development if
they are given market control for the lifespan of their patent.86
However, extensive use of these patent controls also elicits criticism.
Strict patent controls create drug monopolies that theoretically allow
developers to raise prices indiscriminately as high as the market will
allow.87 These drug monopolies can have extremely detrimental effects on
patient outcomes, as patients avoid taking medications or take smaller doses
to save money on prescriptions.88 Additionally, generic-drug companies
were required to complete the same FFDCA process to gain approval as
innovators, an expensive and time-consuming process.89 Rather than using
the trial results and research completed by originators, generic
manufacturers were required to conduct the same tests and repeat research,
despite utilizing equivalent ingredients which would virtually guarantee the
same results. Many generic manufacturers were unable to shoulder the
development costs involved in gaining approval through the FFDCA
process or maintained prices close to the originator drug to afford the costs
of FFDCA approval.90 Because generic manufacturers were saddled with
these costs and unable to significantly lower prices, consumers did not
benefit fully from the presence of generics in the market.
In 1984, the Drug Price Competition and Patent Term Restoration Act,
known as the Hatch–Waxman Act, was passed, with the goal of
“expedit[ing] and streamlin[ing] both generic drug approvals and patent
84
Although there is some overlap, drug companies are typically divided into two categories, which
will be referred to in this Note as originators and generic manufacturers. Originators invest in research
and development and are rewarded with patent protection when they release a drug into the market.
Generic manufacturers develop a bioequivalent, which is given access to the market through HatchWaxman protections. Daniel J. Gifford, Government Policy towards Innovation in the United States,
Canada, and the European Union as Manifested in Patent, Copyright, and Competition Laws, 57 SMU
L. REV. 1339, 1342 (2004).
85
U.S. CONST. art. I, § 8, cl. 8.
86
Ohly, supra note 83.
87
See Werth, supra note 82.
88
Tironi, supra note 16, at 321 (“More than 60 percent of the uninsured chronically ill, and 46
percent of the underinsured chronically ill report skipping medication due to cost.”).
89
Knocke, supra note 80.
90
Allen M. Sokal, The Hatch-Waxman Act: Encouraging Innovation and Generic Drug
Competition,
FINNEGAN
(2010),
available
athttp://www.finnegan.com/resources/articles/
articlesdetail.aspx?news=dfef53ed-54e4-491a-802a-01becb1f47bb.

428

5SALTER.DOCX (DO NOT DELETE)

9/29/15 1:56 PM

Reference Pricing and the United States
35:413 (2015)

litigation involving generic drugs.”91 One of the major provisions of the
Hatch–Waxman Act is a new method of applying for drug approval for
companies that manufacture bioequivalent generics. Instead of repeating the
same cumbersome tests, generic manufacturers can now complete a shorter,
less rigorous application which “piggybacks” the application filed by the
innovator.92 This allows generic manufacturers to save both time and money
when entering the market, making the process smoother and benefitting
both manufacturers and consumers.93
With the advent of the Hatch–Waxman Act, the generic market in the
United States has grown.94 However, the generic market under Hatch–
Waxman depends heavily on price advantages to maintain market share.
Because of this, the generic-market players in the United States might resist
reference pricing, which lowers originator prices and lessens their price
advantage in the market. Likely, generic manufacturers would join
originators in lobbying against this regulation.
2. Medicare & Medicaid
Medicare is “a government health insurance program for individuals
age sixty-five or older, certain disabled persons, and those with kidney
failure who require dialysis (End-Stage Renal Disease, or ERSD).”95
Because reimbursements from Medicare come from a government agency,
Medicare allows for closer price control than the remaining majority of the
U.S. pharmaceutical market.
Medicare covers “services and supplies considered medically
necessary to treat a disease or condition.”96 Though each insurance agency
defines “medically necessary” internally, Medicare defines it as “services or
supplies that are needed to diagnose or treat [a] medical condition and that
meet accepted standards of medical practice.”97 Medicare is divided into
two sections for purposes of providing and reimbursing care and services.
91
Lisa Barons Pensabene & Dennis Gregory, Hatch-Waxman Act: Overview, PRACTICAL L. CO.
(INTEL. PROP. & TECH.), available at http://www.fitzpatrickcella.com/DB6EDC/assets/files/
News/Hatch-Waxman%20Act%20Overview%20lpensabene_dgregory.pdf; Kelly, supra note 18; Ohly,
supra note 83.
92
Ohly, supra note 83.
93
Id.
94
CONG. BUDGET OFF., HOW INCREASED COMPETITION FROM GENERIC DRUGS HAS AFFECTED
PRICES AND RETURNS IN THE PHARMACEUTICAL INDUSTRY 27 (1998), available at
http://www.cbo.gov/sites/default/files/pharm.pdf.
95
Tironi, supra note 16, at 330.
96
What does Part A cover?, MEDICARE, http://www.medicare.gov/what-medicare-covers/parta/what-part-a-covers.html (last visited Sept. 17, 2014.).
97
What does Part B cover?, MEDICARE, http://www.medicare.gov/what-medicare-covers/partb/what-medicare-part-b-covers.html (last visited Sept. 17, 2014).
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Medicare Part A includes hospital care, skilled nursing care, hospice, and
other services.98 Part A originally reimbursed pharmaceutical expenses
directly as an itemized part of hospital costs. However, today Part A covers
hospital expenses as a whole at a flat rate without separately charging for
pharmaceuticals.99 If hospitals are less able to account for fluctuating prices
of drugs, they may have to swallow the costs of drugs which are priced
higher than the reimbursement flat rate for the hospital stay as a whole.100
Medicare Part B, on the other hand, incorporates some of the
principles of price control used in the European Union. Part B covers both
medically necessary services and preventative services.101 Medically
necessary services include “services or supplies that are needed to diagnose
or treat your medical condition and that meet accepted standards of medical
practice.”102 This can include ambulance services, inpatient mental health
services, and durable medical equipment. Preventative services is defined as
“health care to prevent illness . . . or detect it at an early stage, when
treatment is most likely to work best.”103
Part B covers prescription drugs on a limited basis, such as drugs that
are disbursed in the physician’s office.104 These reimbursements have, prior
to 2004, been made based on the Average Wholesale Price (AWP). AWP is
the “sticker price” listed by manufacturers in a national listing of
pharmaceuticals.105 Pharmaceuticals were reimbursed at either 95% of the
AWP or the physician’s billing rate. In 2004, the Medicare Prescription
Drug, Improvement, and Modernization Act (MMA) changed the pricing
model to 106% of the Average Sale Price (ASP), “defined by statute and
based on reports of actual transactions.”106 The ASP pricing model
mechanism allows Medicare to reimburse at lower rates than under the
AWP.107 Though ASP pricing is not externally influenced like reference
pricing, it represents a level of price control that does not exist outside of
Medicare.
Medicaid, another form of government-run health coverage, covers
“some low-income people, families and children, pregnant women, the
elderly, and people with disabilities.”108 Since Medicaid is run on a state98

What does Part A cover?, supra note 96.
Id.
100
Stanton, supra note 1.
101
What does Part B cover?, supra note 97.
102
Id.
103
Id.
104
Tironi, supra note 16, at 331.
105
As Tironi notes, “It is not an actual average of prices paid by wholesalers.” Tironi, supra note 16,
at 331.
106
Id.
107
Id.
108
Medicaid & CHIP coverage, HEALTHCARE.GOV, https://www.healthcare.gov/medicaid99
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by-state basis, prescription drug coverage varies by state. However, many
states utilize limits on prescription reimbursement, often based on AWP.
3. The Office of Veterans Affairs
The Veterans Health Care Act of 1992 established the 340B program,
which “allows certain federally funded grantees and other safety net
providers to purchase prescription drugs at reduced prices.”109 Under 340B,
drug companies must sell to 340B entities at a reduced price, based on a
“340B ceiling price” which “requires discounts of at least fifteen percent of
the Average Manufacturer Price (AMP) for generics.”110 AMP (not to be
confused with AWP) is calculated by a federally regulated formula:
The manufacturer calculates pricing information for all of its
covered outpatient drugs and sends this pricing data to HCFA
within 30 days after the end of the quarter. HCFA will provide
PHS with the data necessary for PHS to determine the ceiling
price which will be used for resolving disputes, studies involving
pricing data, auditing manufacturers, or other program
purposes.111
The 340B program covers the following outpatient drugs: FDAapproved prescription drugs; over-the-counter (OTC) drugs written on a
prescription; biological products that can be dispensed only by a
prescription (other than vaccines); or FDA-approved insulin.112
B. Potential Effects of Reference Pricing on the Pharmaceutical
Industry in the United States
Using international reference pricing would have widespread effects
on the U.S. pharmaceutical industry. Some of these effects can be predicted
by looking to other countries that use international reference pricing.
However, the U.S. pharmaceutical industry is distinctive in its size and
level of innovation. Because of this, the effects on the U.S. market could be
different in terms of innovation, transformational care, black and grey
chip/getting-medicaid-chip/ (last visited Sept. 8, 2014).
109
Tironi, supra note 16, at 334.
110
Id.
111
Notice Regarding Section 602 of the Veterans Health Care Act of 1992; New Drug Pricing, 60
Fed. Reg. 51,488-89 (Oct. 2, 1995), available at http://www.hrsa.gov/opa/programrequirements/
federalregisternotices/newdrugpricing100295.pdf.
112
Eligibility and Registration, U.S. DEP’T OF HEALTH AND HUMAN SERVS.,
http://www.hrsa.gov/opa/eligibilityandregistration/index.html (last visited Nov. 28, 2014).

431

5SALTER.DOCX (DO NOT DELETE)

Northwestern Journal of
International Law & Business

9/29/15 1:56 PM

35:413 (2015)

markets, and patient provider relationships.
1. Innovation
Among developed nations, the United States pharmaceutical market is
unique because of its comparative lack of government price controls. In
particular, the United States features a free market for pharmaceuticals that
is largely unregulated by government controls like reference pricing or price
ceilings.113 As such, pharmaceutical companies are able to charge prices in
the United States that allow them to recoup a portion of the companies’
research and development costs that often go unrecouped in other
markets.114 Patients in the United States pay more than consumers in other
markets. For example, a 2003 study of thirty drugs found that U.S.
consumers paid more for these drugs than consumers in the U.K. and
France.115
“The U.S. biopharmaceutical sector accounts for the single largest
share of all U.S. business R&D, representing nearly 20% of all domestic
R&D funded by U.S. businesses.”116 According to the often-cited Tufts
Center for the Study of Drug Development, U.S. pharmaceutical companies
spend upwards of four billion dollars on research and development on a
single drug.117 GlaxoSmithKline, a major U.S. pharmaceutical company,
spent $81,708 million on research and development from 1997 to 2011, and
costs have only increased in recent years.118 These expenses accumulate
through clinical trials and filing patents, but more often, through drug
failure—fewer than one-in-ten medicines that enter Phase 1 testing make it
into the market.119 These costs are often factored into the costs of drugs that
actually enter the market, at least in the United States where pharmaceutical
companies are able to price in research and development in a free market
system.120
The main issue concerning price reform via government price
regulation in the United States is whether reforms would have a negative
113

Tironi, supra note 16.
See Salomeh Keyhani et al., US Pharmaceutical Innovation in an International Context, 100 AM.
J. PUB. HEALTH 1075 (2010).
115
Knocke, supra note 80, at 181.
116
PHARMACEUTICAL RES. AND MFR. OF AM. (PHRMA), 2013 BIOPHARMACEUTICAL RESEARCH
INDUSTRY PROFILE (2013), available at http://phrma.org/sites/default/files/pdf/PhRMA%
20Profile%202013.pdf.
117
Matthew Herper, The Truly Staggering Cost of Developing New Drugs, FORBES (Feb. 10, 2012,
7:41
AM),
http://www.forbes.com/sites/matthewherper/2012/02/10/the-truly-staggering-cost-ofinventing-new-drugs/.
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119
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impact on pharmaceutical innovation. Most companies within the
pharmaceutical industry, as well as many outside of it, argue that price
reform would dampen innovation.121 The U.S. pharmaceutical market is a
major source of profits for pharmaceutical companies, which allows these
companies to cover losses in other countries. They may not be able to
swallow the costs if the U.S. institutes price controls similar to other
developed nations.
The United States is home to an astoundingly large proportion of
pharmaceutical research and development. Six of the ten largest drug
companies are based in the United States.122 This is perhaps because
pharmaceutical companies are allowed to set prices that let them recoup
research and development costs.123 Many argue that price setting in the
United States, especially under a system of reference pricing intended to
equalize prices between nations, would lead to a decrease in research and
development.124 This decrease would prevent potentially life-saving
medications from eventually reaching not only the United States, but also
the global market.125 The U.S. government has pressured other countries to
limit their price regulation, arguing that price regulations cause the United
States to bear a disproportionate amount of research and development
expenses in order to support “free-rider” countries.126 The U.S. government
has gone so far as to limit price negotiation in the 2003 Medicare
Modernization Act.127 Meanwhile, the pharmaceutical industry has similar
objections. The Pharmaceutical Manufacturers Association of America has
strongly opposed regulation and claimed that foreign governments are
benefitting from U.S. innovation rather than paying their fair share of
development costs.128
However, others argue that price setting in the United States would
have a marginal (if any) effect on research and development overall.129 A
121
Christopher R. Stambaugh, State Price Control Laws Are the Wrong Prescription for the
Problem of Unaffordable Drugs, 12 FORDHAM INTELL. PROP. MEDIA & ENT. L.J. 897, 900 (2002).
122
Trade, Foreign Policy, Diplomacy, and Health: Pharmaceutical Industry, WORLD HEALTH ORG.,
http://www.who.int/trade/glossary/story073/en/ (last visited Nov. 17, 2014).
123
See U.S. DEP’T. OF COMMERCE, INT’L TRADE ADMIN., PHARMACEUTICAL PRICE CONTROLS IN
OECD COUNTRIES: IMPLICATIONS FOR U.S. CONSUMERS, PRICING, RESEARCH AND DEVELOPMENT,
AND INNOVATION (2004) (discussing how government controlled pricing reduces development in
contrast to the United States. “As OECD countries individually seek to reduce spending on drugs
through price controls, their collective actions reduce R&D that would provide substantial health
benefits to all.”), available at http://www.ita.doc.gov/td/chemicals/drugpricingstudy.pdf. Contra
Keyhani, supra note 114.
124
Kraus, supra note 4; Stanton, supra note 1; Shah, supra note 79.
125
Stambaugh, supra note 121.
126
Keyhani, supra note 114, at 1075; Danzon, supra note 15.
127
Keyhani, supra note 114, at 1075.
128
Id. at 1075.
129
Id. at 1077–78.
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2010 study found the following:
[The] United States is important but not disproportionate in its
contribution to pharmaceutical innovation. Interestingly, some
countries with direct price control, profit control, or reference
drug pricing appeared to innovate proportionally more than their
contribution to the global GDP or prescription drug spending.130
In other words, reference pricing is not directly correlated with a
decrease in research and development. Others argue that while the United
States may lead in pharmaceutical innovation, government and grant
funding accounts for a large enough portion of this innovation to
accommodate a decrease in private sector profits. Government funding has
“played an indirect role—for example, by funding basic underlying research
that is built on in the drug discovery process—in almost half of the drugs
approved and in almost two-thirds of priority-review131 drugs.”132
2. Balancing Profit Margins with Transformational Care
Another issue that must be considered in applying reference pricing
systems to the United States is balancing profit margins with the social goal
of pharmaceutical innovation: transformational care. Transformational care
is defined as “radical change introduced by visionary leaders at the level of
the organization.” This can take on many forms, but often includes
openness to new treatments and new medications, which are difficult to
introduce under traditional management models which value continuity.133
The profitability of the pharmaceutical industry allows pharmaceutical
companies to devote money to large-scale innovation.134 These innovations
include medicines that make large leaps in treatment and new therapies.
Without the ability to recoup research and development costs,
pharmaceutical companies may focus instead on cheaper incremental
changes (this argument is similar to the argument often made that generic
drugs limit innovation by discouraging originators, who see their profit
130

Id. at 1078.
Priority review drugs are drugs that, “if approved, would be significant improvements in the
safety or effectiveness of the treatment, diagnosis, or prevention of serious conditions when compared to
standard applications.” When a drug is designated priority review, the FDA takes action on its approval
within six months as opposed to the ten months expected under standard review. Priority Review, FDA
(June 26, 2013), http://www.fda.gov/forpatients/approvals/fast/ucm405405.htm.
132
Bhaven N. Sampat & Frank R. Lichtenberg, What are the Respective Roles of the Public and
Private Sectors in Pharmaceutical Innovation? 30 HEALTH AFFAIRS 332, 332 (2011).
133
Barbara Bigelow & Margaret Arndt, Transformational Change in Health Care: Changing the
Question, 83 HOSPITAL TOPICS 19, 20 (2005).
134
Stanton, supra note 1.
131
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margins shrinking).135 While important, these changes do not achieve the
same level of transformational care that revolutionizes treatment.
3. Grey and Black Market Pharmaceuticals
One potential advantage to reference pricing in the United States is the
decrease in parallel (grey) or black market imports.136 Parallel markets
develop when “a product covered by intellectual property rights in country
A is exported and resold to country B without the right holder’s
authorization”; black markets involve the completely unregulated sale of
drugs.137 Websites, like the now defunct Silk Road (perhaps more known
for its supply of illegal drugs than cheaper but legal pharmaceuticals) and
many other online havens, allow access to lower priced medications in
regulated markets like Canada.138 Import of medications from Canada is a
popular way to gain access to medicines that are prohibitively expensive in
the United States.139
Reference pricing in the United States may lead to lower prices that
more closely equal those of Canada and other regulated nations.140 This
may, in turn, lessen black or grey market importation. This theory, of
course, supposes that reference groups in the United States and reference
groups in countries like Canada, which are currently grey market importers,
would be equivalent. If a drug is priced out of a reference group within the
United States, black or grey market imports might continue or even
increase.
While grey-market imports allow customers to save on prescription
drugs, they also come with risks for the consumer and the pharmaceutical
market. Consumers take a risk when ordering prescription drugs through the
internet or other grey market means of receiving incorrect or potentially
dangerous pills. Additionally, grey markets allow consumers to selfmedicate without the expertise of a doctor to assure a correct diagnosis or a
pharmacist to check dosages or interactions. Drugs without FDA approval
are often obtainable through grey markets, and consumers may be unaware
of damaging effects. Finally, like many Silk Road consumers who were
located through their IP addresses during the government bust of the
135
See generally Beth Understahl, Authorized Generics: Careful Balance Undone, 16 FORDHAM
INTELL. PROP. MEDIA & ENT. L.J. 355 (2005); Greger Vigen, Health Care 2.0—Massive Implications of
System Transformation, HEALTH WATCH 10 (2013).
136
Grey markets, a play on the traditional term “black market” used to refer to illegal sale of goods,
is generally used as a synonym for parallel markets.
137
Kraus, supra note 4, at 540.
138
Id.
139
Kraus, supra note 4.
140
Stanton, supra note 1.
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website, consumers of grey market pharmaceuticals may face legal action.
Even if no conviction results, the costs of such legal action certainly would
exceed the cost of the legal prescription.
Meanwhile, pharmaceutical developers suffer as well. Developers
price their drugs for each country’s market. If sales at a lower price trickle
into another country, these pricing models are no longer effective, and
developers cannot properly estimate their returns on costs.
C. Potential Effects on Patients and Providers
Reference pricing, if instituted in the United States, could have a large
effect on the healthcare industry at the patient and provider level. The
current free-market pharmaceutical pricing in the United States has both
positive and negative effects on providers.
Pricing regulation may lead to pressure on physicians from
pharmaceutical companies to prescribe their products through marketing.141
In recent years, federal and state laws have restricted the use of marketing
(and, through prosecution, attempted to discourage less open tactics like
bribes) to persuade doctors to prescribe certain products. However, in the
past, pharmaceutical companies have gone to extreme measures to get
doctors to prescribe their products, from persuasive “perks” like trips and
gifts to bribes.142 These extreme measures may not have been limited to a
few untoward companies. In 2004, when federal prosecutors began to crack
down on bribery and illegal marketing, “[j]ust about every big global drug
company — including Johnson & Johnson, Wyeth and Bristol-Myers
Squibb — ha[d] disclosed in securities filings that it ha[d] received a
federal subpoena, and most [were] juggling subpoenas stemming from
several investigations.”143 Many of these cases led to sanctions for
pharmaceutical companies, or laws designed to lessen these abuses. In
recent years, this marketing has become smaller in scale, controlled by
federal gift limits and state marketing limitations.144
Reference pricing might impact this smaller scale marketing,
increasing it to levels that more closely mirror the actions the U.S.
government attempted to cut down on in 2004. Pharmaceutical companies
141
Gardiner Harris, MEDICAL MARKETING — Treatment by Incentive; As Doctor Writes
Prescription, Drug Company Writes a Check, N.Y. TIMES (June 27, 2004),
http://www.nytimes.com/2004/06/27/us/medical-marketing-treatment-incentive-doctor-writesprescription-drug-company.html?pagewanted=all&src=pm.
142
See generally Novick v. Dep’t of Health, Bd. of Med., 816 So. 2d. 1237, 1238 (Fla. Dist. Ct.
App. 2002).
143
Harris, supra note 141.
144
For examples of state regulations, see Marketing and Direct-to-Consumer Advertising of
Pharmaceuticals, NAT’L CONF. OF STATE LEGISLATURES (last updated Oct. 2013),
http://www.ncsl.org/research/health/marketing-and-advertising-of-pharmaceuticals.aspx.
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express fear of reference pricing affecting profit margins: “recent
developments threaten to wrest control of pricing, pharmaceutical
companies’ single biggest determinant of profitability, further away from
them.”145 With direct profits out of their hands, the pharmaceutical industry
may react by pressuring doctors to endorse their products which fall outside
the reference group and are not fully reimbursed by government or
insurance payers, meaning patients would have to pay the difference out of
pocket.
D. Interaction with the Affordable Care Act
The Affordable Care Act (ACA), a recent and highly contested piece
of legislation passed by the Obama administration, attempts the difficult
task of both reducing costs and increasing quality and accessibility of care
within the United States. Many of these changes under the ACA will take
place through changes in insurance coverage. Currently, the ACA does not
address reference pricing as a cost saving mechanism for the healthcare
industry. However, reference pricing might be an ideal way to achieve
many of the goals of the ACA.
One of the major goals of the ACA is to extend coverage to all
citizens.146 Reference pricing would certainly make this goal more
affordable for the government. Currently, one of the major criticisms of the
ACA is the eventual cost of insuring the millions of uninsured through
government-funded insurance. By balancing pharmaceutical costs and
placing further regulations on what the government will pay for
pharmaceuticals, reference pricing would lessen the gap between the federal
budget and the cost of insuring every citizen under the ACA.147
Reference pricing would certainly assist in increasing coverage, but
whether the decrease in costs would be sufficient to achieve the ACA’s
tandem goal of reducing costs is uncertain. Likewise, as discussed above,
the ACA’s final goal of improving care may be difficult to achieve as
doctors battle with fewer options in prescribing.
V. CONCLUSION
In a globalized world, it is somewhat surprising that a system like
reference pricing, utilized in every other developed nation and so
entrenched in foreign pharmaceutical markets, is not used in the United

145

Pharmaletter, supra note 48.
Goal 1: Strengthen Health Care, HHS.GOV, http://www.hhs.gov/secretary/about/goal1.html.
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John Cogan et al., A Better Way to Reform Healthcare, WALL ST. J. (Feb. 24 2010, 7:02 PM),
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States. Certainly, there are downsides to reference pricing, most notably the
potential harm to global research and development that would occur.
However, the positive factors are substantial, such as a decrease in prices
for consumers and government spenders. Overall, it seems that reference
pricing in the United States may have a small negative effect on global
markets, but an overall positive effect on consumers and providers in the
United States, which far outweighs those factors.
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